Part IV · Decision guide
How to think about regain
If you have lost weight and it came back, you already know the experience. What is less widely known is how precisely that outcome was predicted.
The short answer
Regain is the predictable behavior of a regulated system, not a failure of character. In the one study that measured it, appetite rose by about 100 calories a day for each kilogram lost, more than three times the fall in energy expenditure. The useful responses are to protect muscle and to plan for the hunger.
Regain is the system working
Weight coming back is not a failure of character. It is what a regulated system does when it is moved away from the level it is defending. Two things happen reliably, and both push in the same direction.
+100 kcal/day
Added eating drive per kilogram lost C-III-06
−250–400 kcal/day
Fall in energy expenditure below predicted, after ~10% loss C-III-04
In practical terms, you become hungrier and burn less at the very point when you are trying to hold a loss.
The hunger is real and lasts longer than most people expect
Twelve months after a diet ends, the hormones have not returned to normal. In the New England Journal of Medicine study that followed participants for a year after a diet, leptin sat around 35% below its starting level, ghrelin remained elevated, and measured hunger ran higher than it had before the diet began.C-II-04
That is a full year of a signal still being sent, rather than a brief period of adjustment.
What the popular account gets wrong
You will often read that weight loss permanently damages your metabolism by around 500 calories a day. That figure comes from a 14-person study of contestants who had regained most of their weight. Four independent studies of people who successfully maintained a loss found resting metabolic rate within a few percent of predicted, with no permanent obligatory deficit.C-III-05
The correction matters in a specific way: it moves the problem from metabolism, which you can do little about, to appetite, which is what every effective intervention acts on.
Time helps, with a caveat
Among people who have maintained a loss, the odds of regain were substantially lower for those who had held it for two to five years, and lower still beyond five.C-III-10 That is encouraging, and it is also a survivor statistic: these are self-selected cohorts of people for whom maintenance worked, with no record of everyone for whom it did not. The figures describe who is in the room, not your own odds.
What successful maintainers do
812 kcal/day
Physical activity expenditure in people sustaining a large loss
12,100
Steps a day, against about 8,900 in normal-weight controls C-III-11
What these figures describe is not a body that has stopped fighting but a group of people who kept outspending the defense.
Regain after treatment
After stopping a medication, regain is expected rather than surprising: roughly two-thirds of the loss returned in the best-documented case.C-III-09 The effect is present for as long as the treatment is. If stopping is the plan, this is what to plan for.
After a procedure, the picture is less tidy than headline figures suggest, because it depends on who is counted. At twenty-four months, 84.2% of those still in follow-up had lost at least 10% of their body weight. Measured across everyone who enrolled, the figure was 53%.C-IV-04
A procedure is not a category apart here. Medications and bariatric surgery sit in one mechanistic category, differing in degree rather than kind, and ESG acts on appetite-related physiology through a different lever again.C-IV-09 Neither switches the defense off.
What helps
None of this amounts to advice to try harder. The defense responds to being outlasted, or to being acted on directly, rather than to effort.
What the evidence supports is unglamorous. Whichever intervention you use, it works for as long as it is working, and two practices help regardless of route. The first is to protect muscle, because a meaningful share of what comes off is lean tissue and resistance training preserves itC-IV-08. The second is to expect the hunger and plan around it, rather than treating each hungry day as evidence about your character.
References
- Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. NEJM. 2011. DOI 10.1056/NEJMoa1105816
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010. PMC3673773
- Fothergill E, et al. Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition. Obesity. 2016. PMC4989512
- Wyatt HR, et al. Resting energy expenditure in reduced-obese subjects in the National Weight Control Registry. Am J Clin Nutr. 1999. PMID 10357738
- Ostendorf DM, et al. No consistent evidence of a disproportionately low resting energy expenditure in long-term successful weight-loss maintainers. Am J Clin Nutr. 2018. PMID 30321282
- Martins C, et al. Metabolic adaptation is not a major barrier to weight-loss maintenance. Am J Clin Nutr. 2020. PMID 32386226
- Martins C, et al. Metabolic adaptation is an illusion, only present when participants are in negative energy balance. Am J Clin Nutr. 2020. PMID 32844188
- Clamp LD, et al. Successful and unsuccessful weight-loss maintainers: strategies to counteract metabolic compensation following weight loss. J Nutr Sci. 2018. PMID 29988905
- Polidori D, et al. How Strongly Does Appetite Counter Weight Loss? Obesity. 2016. PMID 27804272
- Speakman JR, et al. Set points, settling points and some alternative models. Dis Model Mech. 2011. PMID 22065844
- Models of body weight and fatness regulation. Phil Trans R Soc B. 2023. PMC10475878
- Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP 1 extension). 2022. PMID 35441470
- Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005. PMID 16002825
- Ostendorf DM, et al. Physical Activity Energy Expenditure and Total Daily Energy Expenditure in Successful Weight Loss Maintainers. Obesity (Silver Spring). 2019. PMID 30801984
- Lopez-Nava G, et al. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. Obes Surg. 2017. PMID 28451929
- Anyiam O, et al. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obes Rev. 2025. PMID 40181228
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. PMID 38937282
- Mechanick JI, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025. PMID 39295512
- Linge J, et al. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. 2024. PMID 39401279
- Schwartz MW, Seeley RJ, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017. PMC5546881